Today: 20 May 2026
Woodside share price rises as WDS flags softer 2026 output, oil jumps on Iran fears
29 January 2026
2 mins read

Woodside share price rises as WDS flags softer 2026 output, oil jumps on Iran fears

SYDNEY, Jan 29, 2026, 17:08 AEDT — The market has closed.

  • Woodside shares ended the day 0.7% higher, closing at A$25.16.
  • The company forecasted 2026 output to fall short of last year’s record, citing scheduled downtime at Pluto LNG and the timing of Scarborough.
  • Traders are eyeing oil’s geopolitical premium and Australia’s Feb. 3 rate decision as Woodside gears up to report on Feb. 24.

Woodside Energy Group (WDS.AX) shares ended Thursday up 0.7%, closing at A$25.16. The gains came despite initial jitters over the company’s reduced production forecast for 2026.

The stock’s late-week surge is key as Woodside looks to lock in gains off record 2025 production. This comes ahead of a maintenance-heavy stretch this year and a more gradual Scarborough ramp-up.

Oil is pulling its weight as well. The local rate talk has shifted following hotter inflation data, and that ripple effect is coloring the broader market mood—even though the trigger lies beyond energy.

Woodside’s latest report set the tone. December-quarter revenue dropped 13% year-on-year to $3.04 billion, dragged down by average realised prices slipping to $57 a barrel of oil equivalent (boe) — a common unit that converts gas output into oil terms. The company left Scarborough’s progress steady at 94% complete and maintained its 2026 production guidance between 172 million and 186 million boe. Acting CEO Liz Westcott said, “We are looking forward to first LNG from Scarborough in the fourth quarter of this year.” Company Announcements

Woodside submitted that quarterly update for U.S. investors in a Form 6-K filing with the Securities and Exchange Commission on Jan. 28.

Analyst Nik Burns of Jarden noted the market had already factored in weaker 2026 production and would probably “take it in its stride,” recalling how Woodside began last year cautiously before upgrading twice. Saul Kavonic from MST Marquee added the result underscores a move toward more conservative guidance. Reuters

Commodity markets are fueling the move. Brent crude gained 1.5% to $69.39 a barrel in Asian trading, while U.S. WTI jumped 1.7% to $64.27. Reuters highlighted rising worries that the U.S. might launch an attack on Iran, a key OPEC supplier. Priyanka Sachdeva, an analyst at Phillip Nova, pointed to the growing U.S.-Iran tensions as a key factor driving the “supply-risk narrative.” Reuters

Australian rate expectations firmed after underlying inflation came in hotter than anticipated. The trimmed mean CPI — which excludes the most volatile prices — jumped 0.9% in the December quarter, pushing the annual rate to 3.4%, Reuters reported. Swaps now price in a 73% chance of a rate hike at the Reserve Bank of Australia’s Feb. 3 meeting. “Alongside strong labor market data and capacity constraints, the case for tighter monetary policy is clear,” said Cherelle Murphy, EY’s chief economist. Reuters

Woodside’s longer-term options resurfaced this week with Greater Sunrise back in focus. Australian Prime Minister Anthony Albanese and Timor-Leste’s Xanana Gusmao called on the joint venture to push ahead “as soon as possible.” This follows Woodside and Timor-Leste’s December agreement to explore a 5 million-tonne-per-year LNG project for the field, which holds an estimated 5.1 trillion cubic feet of gas, Reuters reported. Reuters

The next move for the stock won’t be straightforward. A drop in crude prices could quickly put pressure on bids. On top of that, any delays in project timelines or a prolonged Pluto shutdown would weigh on volumes—just when investors want clear answers on costs, cash returns, and who will take over as CEO.

Friday’s session kicks off with a focus on oil prices and the latest rate updates. Traders will then shift their attention to the Feb. 3 RBA decision, followed by Woodside’s full-year results and briefing set for Feb. 24.

Stock Market Today

  • Sea Limited (NYSE:SE) Valuation Under Scrutiny After 46% One-Year Share Decline
    May 20, 2026, 10:05 AM EDT. Sea Limited (NYSE:SE), active across e-commerce, digital financial services, and digital entertainment in Southeast Asia and Latin America, has seen its stock fall by 46.26% over the past year. Despite recent share price weakness, some analysts argue the stock trades 36.6% below a $137.64 fair value estimate, buoyed by strong revenue growth from Shopee, Monee, and Garena platforms. Key drivers include accelerating mobile internet penetration, youth digital literacy, and shifts toward cashless payments supporting loan book expansion and improved monetization. Market watchers debate whether this dip offers a buying opportunity or reflects tempered growth prospects, especially as Shopee faces competitive pressures. Investors should weigh Sea's potential for earnings growth against market realities and execution risks.

Latest articles

Vida CEO Steps In as $15 Million AI IPO Hits Reality Check

Vida CEO Steps In as $15 Million AI IPO Hits Reality Check

20 May 2026
Vida Global Inc. raised $15 million in its May 18 IPO, selling 3.75 million shares at $4 each, but the stock closed at $2.29 on Tuesday. CEO Lyle Pratt bought 312,900 shares for about $1.19 million, according to a Form 4 filing. Vida reported 2025 revenue of $551,383 and a net loss of $2.9 million. The company’s shares trade on NYSE American and NYSE Texas under the symbol VIDA.
TJX Shares Rise Premarket As T.J. Maxx Parent Raises Outlook

TJX Shares Rise Premarket As T.J. Maxx Parent Raises Outlook

20 May 2026
TJX raised its fiscal 2027 sales, earnings, and buyback targets after first-quarter comparable sales rose 6% and net income hit $1.3 billion. Shares climbed 3.6% in premarket trading. The company cited higher fuel costs as a drag on its full-year forecast. Marmaxx, HomeGoods, and TJX Canada all posted strong sales growth.
ImmunityBio in the Spotlight with Patents and BCG Deal Ahead of the Open

ImmunityBio Faces FDA Decision on Bladder-Cancer Application, Risk Remains

20 May 2026
The FDA accepted ImmunityBio’s application to expand Anktiva’s use with BCG in papillary-only, BCG-unresponsive non-muscle invasive bladder cancer, setting a Jan. 6, 2027 decision date. ImmunityBio reported $44.2 million in first-quarter net product revenue and held $380.9 million in cash and equivalents. Shares last traded at $7.76, down 2.8%. The filing is supported by data from 80 patients in a Phase 2/3 trial.
Wall Street Feels the Heat (and Thrill): Fed Cuts, Tariffs & Mega-Mergers Set NYSE Buzz
Previous Story

Stock Market Today 29.01.2026

iFAST share price slides 2.6% after Tembusu-linked stake trim; Feb 12 results in focus
Next Story

iFAST share price slides 2.6% after Tembusu-linked stake trim; Feb 12 results in focus

Go toTop